✦ LIBER ✦

The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis

✍ Scribed by Stuart Mealing,Leticia Barcena,Neil Hawkins…

Book ID: 126381487
Publisher: BioMed Central
Year: 2013
Tongue: English
Weight: 309 KB
Volume: 2
Category: Article
ISSN: 2162-3619
DOI: 10.1186/2162-3619-2-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Major molecular response during the firs

Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: A network meta-analysis

✍ Signorovitch, James; Ayyagari, Rajeev; Reichmann, William M.; Wu, Eric Q.; Chen, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 406 KB

High-dose imatinib for newly diagnosed c

High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients—Systematic review and meta-analysis

✍ Anat Gafter-Gvili; Avi Leader; Ronit Gurion; Liat Vidal; Ron Ram; Adi Shacham-Ab 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 319 KB 👁 1 views

## Abstract Imatinib at a dose of 400 mg daily is considered frontline treatment in chronic phase chronic myeloid leukemia (CP‐CML). We conducted a systematic review and meta‐analysis of randomized controlled trials comparing frontline treatment with imatinib 400 mg daily versus higher doses (≥600

Comparative efficacy of nilotinib and da

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials

✍ Signorovitch, James E.; Wu, Eric Q.; Betts, Keith A.; Parikh, Kejal; Kantor, Eva 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 190 KB

PCN86 Cost-Utility Analysis of Nilotinib

PCN86 Cost-Utility Analysis of Nilotinib Compared to Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase

✍ Inocencio, T.J.; Seetasith, A.; Newland, A.; Bose, P.; Holdford, D. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PCN63 The Relative Value of Dasatinib Ve

PCN63 The Relative Value of Dasatinib Versus Imatinib as First-Line Treatment for Chronic Myeloid Leukemia

✍ L. Betegon; I. Gilloteau; P. Martin; A. Woolmore; I. Oyagüez 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Efficacy and safety of dasatinib versus

Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up

✍ Fujisawa, Shin; Nakamae, Hirohisa; Ogura, Michinori; Ishizawa, Ken-ichi; Taniwak 📂 Article 📅 2013 🏛 Carden Jennings Publishing 🌐 English ⚖ 367 KB